Suchergebnisse - "Byrd, John"

PubPharm (640)

1

Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia

enthalten in: JCI insight | 2024

von Elgamal, O. | Fobare, S. | Vibhute, S. | +30

2

Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL : Pooled analysis of 5 clinical trials

enthalten in: Blood advances | 2024

von Davids, M. | Sharman, J. | Ghia, P. | +9

3

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

enthalten in: Blood | 2024

von Woyach, J. | Perez Burbano, G. | Ruppert, A. | +29

4

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation : An International, Multicenter, Retrospective Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Kittai, A. | Bond, D. | Huang, Y. | +30

5

A Bayesian framework to study tumor subclone-specific expression by combining bulk DNA and single-cell RNA sequencing data

enthalten in: Genome research | 2024

von Qiao, Y. | Huang, X. | Moos, P. | +7

6

Inhibition of Enhancer of Zeste Homolog 2 Induces Blast Differentiation, Impairs Engraftment and Prolongs Survival in Murine Models of Acute Myeloid Leukemia

enthalten in: Cancers | 2024

von Fobare, S. | Elgamal, O. | Wunderlich, M. | +13

7

Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)

enthalten in: Leukemia | 2024

von Ozga, M. | Nicolet, D. | Mrózek, K. | +37

8

A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML

enthalten in: Blood advances | 2024

von Cai, S. | Huang, Y. | Lance, J. | +35

9

A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment

enthalten in: Blood advances | 2024

von Wang, L. | Leach, V. | Muthusamy, N. | +2

CommentIn: Blood Adv. 2024 Jan 23;8(2):482-483. - PMID 38261330

10

First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma

enthalten in: Cancer discovery | 2024

von Woyach, J. | Stephens, D. | Flinn, I. | +13

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[64]